Antibiotics (Inhaled) - Arikayce
Customize your policy alerts
Sign up for Cigna Policy IP0383 alerts
Get alerted when Policy IP0383 changes without checking for updates manually.
Monitor payer policy activity
Prior authorization and medical-necessity coverage for Arikayce in adults with refractory MAC lung disease and for cystic fibrosis-associated Pseudomonas aeruginosa infection, subject to specified clinical and specialist-treatment criteria.
For initial MAC lung disease therapy, the policy replaced the refractory-disease wording with requirements for completion of at least 6 consecutive months of background multidrug therapy and a positive MAC sputum culture.
The policy title was updated from Amikacin Liposome to Antibiotics (Inhaled) - Arikayce Prior Authorization Policy.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.